Araujo, J., Mathew, P., Armstrong, A. J., Braud, E. L., Posadas, E., Lonberg, M., … Logothetis, C. J. (2009). 7028 Dasatinib and docetaxel combination treatment for patients with metastatic castration-resistant prostate cancer (CRPC): analysis of Study CA180–086. In European Journal of Cancer Supplements (Vol. 7, pp. 415–415). Elsevier BV. https://doi.org/10.1016/s1359-6349(09)71406-5

Araujo, J., P. Mathew, A. J. Armstrong, E. L. Braud, E. Posadas, M. Lonberg, G. Gallick, G. C. Trudel, P. Paliwal, and C. J. Logothetis. “7028 Dasatinib and docetaxel combination treatment for patients with metastatic castration-resistant prostate cancer (CRPC): analysis of Study CA180–086.” In European Journal of Cancer Supplements, 7:415–415. Elsevier BV, 2009. https://doi.org/10.1016/s1359-6349(09)71406-5.

Araujo J, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, et al. 7028 Dasatinib and docetaxel combination treatment for patients with metastatic castration-resistant prostate cancer (CRPC): analysis of Study CA180–086. In: European Journal of Cancer Supplements. Elsevier BV; 2009. p. 415–415.

Araujo, J., et al. “7028 Dasatinib and docetaxel combination treatment for patients with metastatic castration-resistant prostate cancer (CRPC): analysis of Study CA180–086.” European Journal of Cancer Supplements, vol. 7, no. 2, Elsevier BV, 2009, pp. 415–415. Crossref, doi:10.1016/s1359-6349(09)71406-5.

Araujo J, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick G, Trudel GC, Paliwal P, Logothetis CJ. 7028 Dasatinib and docetaxel combination treatment for patients with metastatic castration-resistant prostate cancer (CRPC): analysis of Study CA180–086. European Journal of Cancer Supplements. Elsevier BV; 2009. p. 415–415.